Bausch + Lomb’s third quarter results were met with a notably positive market response, reflecting investor enthusiasm for the company’s ability to expand margins while delivering steady revenue growth across all business segments. Management attributed the performance to disciplined execution and a broad-based contribution from pharmaceuticals, surgical products, and vision care. Interim CEO Tom Appio emphasized the importance of ongoing portfolio strength and operational improvements, stating, “We are building momentum across the business and the trajectory is encouraging.” The quarter was further defined by strong cash generation and continued progress in margin expansion initiatives.
Is now the time to buy BLCO? Find out in our full research report (it’s free for active Edge members).
Bausch + Lomb (BLCO) Q3 2026 highlights:
- Revenue $1.38 billion vs S&P analysts’ estimates of $1.37 billion (7.3% year-on-year growth, in line)
- Adjusted EPS $0.34 vs S&P analysts’ estimates of $0.22 (54.7% beat)
- Adjusted EBITDA $325 million vs analyst estimates of $270.9 million (23.6% margin, 20% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $5.5 billion at the midpoint from $5.49 billion
- EBITDA guidance $1.12 billion at the midpoint for the full year, above analyst estimates of $1.05 billion
- Operating margin 11.3%, up from 7.4% in the same quarter last year
- Constant currency revenue rose 8% year on year (6% in the same quarter last year)
- Market capitalization $7.29 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from Bausch + Lomb’s Q3 earnings call
- Patrick Wood (UBS) asked about the rationale for recent leadership changes amid strong performance; Interim CEO Tom Appio reiterated the board’s focus on operational excellence and accelerating R&D pipeline delivery.
- Young Li (Jefferies) inquired about specific operational changes under new management; Appio pointed to greater emphasis on SG&A efficiencies, continued top-line growth, and careful capital allocation between debt reduction and business investment.
- Leigh Huang (Wells Fargo) pressed on the drivers behind margin gains and the long-term EBITDA margin target; CFO Osama A. Eldessouky detailed the importance of product mix, cost discipline, and ongoing network optimization initiatives.
- Anthony (Citi) probed trends in the contact lens market and competitive dynamics; Appio and Eldessouky described broad-based strength, with U.S. growth outpacing international markets, and highlighted Project Halo’s potential to drive future differentiation.
- Kieran Ryan (Deutsche Bank) sought updates on the R&D pipeline, especially dry AMD programs; Chief Medical Officer Yehia Hashad provided detail on promising clinical progress, including FDA interactions for orally administered therapies addressing unmet needs.
Catalysts in upcoming quarters
In the quarters ahead, we will monitor (1) the pace of adoption for premium IOLs and next-generation contact lenses, (2) progress on key clinical milestones for pipeline products such as Project Halo and dry AMD therapies, and (3) continued execution on SG&A efficiency and manufacturing productivity initiatives. Developments in capital allocation and leverage reduction will also be important signals of management’s ability to balance growth with financial discipline.
Bausch + Lomb currently trades at $20.19, up from $17.62 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
The best stocks for high-quality investors
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
